🪐COSMOS trial in PsA🪐 #ACR22 @RheumNow Abstract #2110 ⭐️285 pt. failed to respond to TNFi ⭐️Guselkumab 100 mg q8w vs. PBO (crossed over GUS at 16 or 24w) ⭐️response to GUS as early as 8w and did not plateau by 48w ⭐️By 48w, 30-33% pts. achieved min. disease activity